Viz.ai, Inc. Overview
Pro stress-test →Viz.ai is a subscription SaaS company that provides AI-powered disease detection and care coordination solutions to hospitals and health systems. The company's platform leverages over 50 advanced, FDA-cleared algorithms to analyze a range of imaging modalities—including CT scans, EKGs, and echocardiograms—providing automated assessments that accelerate diagnosis, streamline clinical workflows, and enable faster treatment decisions. As of January 2026, the company has reached profitability in its healthcare business.
Strategic Profile
Pro stress-test →The Viz.ai platform includes several specialized solutions such as Viz.ai One™, Viz Neuro Suite, Viz Vascular Suite, Viz Cardio Suite, Viz Trauma Suite, Viz Radiology Suite, and Viz Life Sciences. This business doubled over the prior 18 months to reach 13 strategic partnerships, with 6 new pharma partnerships added in 2025 alone, allowing pharmaceutical companies to accelerate product launches and improve patient access to new therapies. The company has established multi-year partnerships with major pharmaceutical companies to deploy disease-specific AI workflows, including Sanofi and Regeneron for AI-powered COPD workflows and Novartis for oncology workflows.
Competitive Landscape
Pro stress-test →Viz.ai's top competitors include Medidata, IQVIA and Verily. Viz.ai differentiates through broad FDA-cleared algorithm portfolio, integrated care coordination platform, and proven clinical outcomes. The company's profitability status and pharma partnerships position it ahead of venture-backed competitors still scaling clinical adoption.
Industry Context
Viz.ai, Inc. operates in Clinical AI decision support platforms.
Key facts
Founded: 2016 · Headquarters: San Francisco, US · Employees: Not disclosed · Revenue: Not disclosed